OrthoPediatrics (KIDS) reported $61.25 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 12.2%. EPS of -$0.24 for the same period compares to -$0.18 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $62.59 million, representing a surprise of -2.14%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being -$0.26.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales by category- Trauma and deformity: $44.14 million versus the three-analyst average estimate of $44.65 million. The reported number represents a year-over-year change of +17.3%.
- Product sales by category- Sports medicine/other: $0.85 million versus the three-analyst average estimate of $1.13 million. The reported number represents a year-over-year change of -34.7%.
- Product sales by category- Scoliosis: $16.26 million compared to the $16.8 million average estimate based on three analysts. The reported number represents a change of +4% year over year.
View all Key Company Metrics for OrthoPediatrics here>>>
Shares of OrthoPediatrics have returned -7.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OrthoPediatrics Corp. (KIDS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
